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Introduction
Relief of right ventricular (RV) outflow tract obstruction in tetralo-
gy of Fallot (TOF) or similar physiology often results in pulmonary re-
gurgitation (PR). The resultant chronic volume overload can lead 
to RV dilatation, biventricular dysfunction, heart failure symptoms, 
arrhythmias and sudden death.
1-5) Pulmonary valve replacement 
(PVR) can lead to improvement in the functional class and a sub-
stantial decrease or normalization of RV volumes.
6)7) However, there 
are some unsolved problems related to PVR in patients with chronic 
PR. These include optimal valve substitute for PVR and optimal tim-
ing of PVR in asymptomatic patients. This article reviews the patho-
physiology of chronic PR, evidence-based benefits and risks of PVR, 
options for valve substitute, and optimal timing of PVR in patients 
with chronic PR after relief of RV outflow tract obstruction.
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Pathophysiology of Chronic Pulmonary  
Regurgitation
Although PR resulting from relief of RV outflow tract obstruction 
(most typically after transannular repair of TOF) was originally con-
sidered to be a benign lesion, it is now evident that chronic PR can 
cause progressive RV dilatation and dysfunction as a consequence 
of chronic volume overload. PR is often well tolerated during child-
hood and adolescence. However, if left untreated, chronic PR can ul-
timately lead to heart failure symptoms, arrhythmias, and most im-
portantly, sudden death. These clinical deteriorations typically ma-
nifest after the second postoperative decade.
1)3)4) Fig. 1 shows the 
pathophysiologic consequences of chronic PR.
Currently, magnetic resonance imaging (MRI) is regarded as a gold 
standard for evaluating RV volumes and function
8) and studies us-
ing MRI have led to a deeper understanding of the pathophysio-
logic consequences of chronic PR. Several studies have demonst-
rated a close correlation between the degree of PR and RV diastolic 
volumes (Fig. 2).
9-11) As long as the compensatory mechanisms of 
the RV work, RV end-systolic volume and ejection fraction (EF) are 
maintained within a normal range. However, similar to chronic aor-
tic regurgitation, once the compensatory mechanisms of RV fail, 
RV end-systolic volume increases and RV EF decreases (Fig. 3). Al-
though decreased RV systolic function plays a central role in clinical 
deterioration of patients with chronic PR, concurrent left ventricular 
(LV) systolic dysfunction is also known to contribute to clinical de-2  Surgical Management of Chronic Pulmonary Regurgitation
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terioration. Geva et al.
4) demonstrated that LV systolic dysfunction 
was independently associated with impaired clinical status in long-
term survivors of TOF repair. A study by Knauth et al.
12) also showed 
similar results. The so-called “RV-LV interaction” plays an important 
role in the development of LV systolic dysfunction seen in some 
patients with chronic PR and RV systolic dysfunction. Because the 
RV shares myocardial fibers with the LV,
13) dysfunction of RV can 
adversely impact the function of LV. Studies using MRI have dem-
onstrated this “RV-LV interaction” by showing correlations be-
tween RV EF and LV EF.
4)14)
Sudden cardiac death is the most dreadful consequence of chronic 
PR and the most common mode of death in patients with repaired 
TOF.
1) The annual incidence of sudden cardiac death is known to be 
approximately 0.15% per year in long-term survivors of TOF repair.
15) 
Several studies have identified risk factors for sudden cardiac death 
late after TOF repair. Gatzoulis et al.
3)16)17) in a study of 178 adult sur-
vivors of TOF repair, reported that chronic RV volume overload cor-
related with QRS prolongation and the risk of symptomatic ar-
rhythmia was high when marked RV enlargement and QRS prolon-
gation developed. A QRS duration of 180 ms or more was the most 
sensitive predictor of life-threatening ventricular arrhythmias. Gat-
zoulis et al.,
3) in a multicenter study that consisted of 793 patients 
with repaired TOF, reported that QRS duration of 180 ms or more 
was predictive of ventricular tachycardia (VT) and sudden death. 
They found that the electrophysiological and hemodynamic sub-
strate of sudden death resembled that of sustained VT, with PR be-
ing the predominant hemodynamic lesion.
Benefits and Risks of Pulmonary Valve 
Replacement
Most studies dealing with PVR in patients with chronic PR have 
consistently reported subjective improvements in functional cl-
ass.
18-22) However, there are conflicting results regarding objective 
improvements in exercise capacity as assessed by cardiopulmonary 
exercise tests. Ghez et al.
23) reported that although most patients 
showed clinical improvement after PVR, maximal exercise capacity 
as assessed by maximal oxygen consumption did not improve after 
PVR. Frigiola et al.
20) also found that there was no improvement in 
Fig. 2. Correlation between pulmonary regurgitation and right ventricular 
(RV) end-diastolic volume index in 206 patients with repaired TOF.
9) TOF: te-
tralogy of Fallot.
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Fig. 3. Relationship between right ventricular (RV) end-systolic volume and 
RV ejection fraction in 100 patients with repaired TOF.
8) TOF: tetralogy of 
Fallot, RV ES; right ventricular end-systolic, BSA; body surface area.
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Fig. 1. Factors influencing right ventricular (RV) dysfunction and impaired 
clinical status after TOF repair.
8) LV: left ventricular, TOF: tetralogy of Fallot, 
RBBB: right bundle branch block, RVESVI: right ventricular end-systolic vol-
ume index, RVOT: right ventricular outflow tract, VT: ventricular tachycardia.
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maximal oxygen consumption after PVR. However, they reported 
that the ventilatory response to carbon dioxide production at anaer-
obic threshold improved after PVR and normalization of the venti-
latory response to carbon dioxide production was most likely to oc-
cur when PVR was performed at an age younger than 17.5 years.
Numerous studies using MRI have confirmed a substantial decrea-
se or normalization of RV volumes after PVR.
7)18-20) Oosterhof et al.,
19) 
in a study of 71 patients with repaired TOF, showed a decrease in RV 
volumes of approximately 30% after PVR and reported that they 
could not find a threshold above which RV volumes did not decrease 
after surgery.
19) There is a question of whether the reported decrease 
in RV volumes after PVR is merely the result of surgical RV reduction 
(resection or plication of RV outflow tract aneurysm). Although 
surgical RV reduction at the time of PVR can result in a greater re-
lative decrease in RV volumes, substantial decrease in RV volumes 
was also noted in patients who did not undergo surgical RV reduc-
tion.
19) Interestingly, two large studies using MRI have found that 
LV end-diastolic volumes significantly increased after PVR, suggest-
ing a reversal of the adverse RV-LV interaction.
19)20)
Although PVR can consistently lead to a substantial decrease of 
RV volumes, improvement in RV systolic function has not been uni-
formly demonstrated. Studies reporting no improvement of RV 
function had patients with already depressed RV function (RV EF 
<49%), whereas studies reporting improvement in RV function had 
patients with preserved RV function.
7)20)23-26) This implies that PVR 
should be performed before irreversible RV dysfunction occurs. 
Some authors have advocated the use of corrected RV EF (calcu-
lated after excluding the PR volume) to demonstrate improvement 
in RV function after PVR.
27)
There are conflicting results regarding the impact of PVR on QRS 
duration and arrhythmia propensity, and this may be due to the dif-
ferent characteristics of the study population. Studies reporting no 
change of QRS duration had patients with relatively longer baseline 
QRS duration or larger RV volumes compared with those reporting 
improvement in QRS duration.
19)26)28-30) This implies that timely PVR 
before the occurrence of severe RV dilatation may have a beneficial 
effect on QRS duration
Currently, there is no data showing a clear long-term survival be-
nefit of PVR. Gengsakul et al.,
30) in a matched comparison study, re-
ported that there was no difference regarding the composite out-
come of death and VT between PVR and non-PVR subjects. Recently, 
Harrild et al.
26) also reported similar results. Long-term follow-up re-
sults of carefully designed studies are mandatory to draw a defini-
tive conclusion on this important issue.
Benefits of PVR have to be weighed against the risks of this pro-
cedure. Nowadays, PVR can be performed with low operative mor-
tality. Cheung et al.,
6) in a meta-analysis of PVR after TOF repair, re-
ported that the pooled early mortality rate was 2.1% (95% con-
fidence interval 1.1% to 4.0%). The majority of patients experience 
an uncomplicated postoperative course, although postoperative 
morbidities are not negligible.
31) Most importantly, patients are ex-
posed to the risk of repeat PVR and this is a weak aspect of deter-
mining the optimal timing of PVR.
Valve Options for Pulmonary Valve Replacement
There are several valve options for PVR, including bioprostheses, 
homografts, mechanical valves, and hand-sewn polytetrafluoro-
ethylene valves. Among these, bioprosthetic valves are probably 
the most widely used because they are readily available and do not 
need permanent anticoagulation therapy. However, most of these 
bioprostheses will eventually fail and require replacement mainly 
due to structural valve deterioration and more specifically, leaflet 
calcification. Although modern design techniques and anti-calcifi-
cation treatments applied to currently available bioprosthetic valves 
have greatly improved the durability of bioprostheses implanted 
into adult patients,
32)33) dystrophic calcification leading to early bio-
prosthetic valve failure is still a great problem in children and young 
adults. A dominant risk factor predictive of early bioprosthetic pul-
monary valve failure is a younger age at the time of initial PVR, as 
reported in previous studies.
34)35) Currently, the exact cause and 
mechanism of accelerated bioprosthetic valve failure in children is 
not completely understood. Traditionally, active calcium metabo-
lism of rapidly growing children has been regarded as a culprit. More 
recently, however, some evidence suggests that greater immune 
system competence of children and young adults may contribute 
to accelerated bioprosthetic valve failure.
36-38) Recently, we report-
ed that although bioprosthetic pulmonary valve function was sta-
bly maintained until 5 years after PVR, about 80% of the patients 
will require reoperation or manifest valve dysfunction in 10 years 
(Fig. 4).
39) The reported durability of bioprosthetic valves in the pul-
monary position is summarized in Table 1.
Some centers prefer homograft as a valve substitute for PVR. 
However, homograft has a drawback of limited availability and also 
fails in the long term. van de Woestijne et al.
47) reported that relief 
from redo PVR was 70% at 15 years in a recent study of PVR using 
homograft after TOF repair. Oosterhof et al.
48) reported that relief from 
homograft dysfunction was 47% at 10 years.
There is limited experience in implanting mechanical valves in the 
pulmonary position.
49-51) Although mechanical pulmonary valves are 
expected to be more durable than bioprosthetic valves and homo-
grafts, permanent anticoagulation carries inherent risk of serious 
bleeding events and can impair the quality of life in children and 
young adults. Currently, it seems reasonable that mechanical PVR 4  Surgical Management of Chronic Pulmonary Regurgitation
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can be considered in highly selected patients with multiple prior op-
erations or another need for anticoagulation such as the presence 
of mechanical valve in other positions.
In an effort to overcome the limited durability of bioprosthetic val-
ves in the pulmonary position, Quintessenza et al.
52)53) introduced a 
new method of implanting a bicuspid pulmonary valve using polytet-
rafluoroethylene (PTFE) material (Fig. 5). Their rationale for the de-
velopment of this technique was based on favorable experimental 
and clinical results of PTFE monocusp valve.
54) Earlier, they used 0.6 
mm thickness PTFE material and experienced a few cases of redo 
PVR due to immobile and calcified leaflets.
55) Freedom from redo 
PVR of this valve was approximately 70% at 8 years. Currently, 
they are using 0.1 mm thickness PTFE membrane anticipating im-
proved valve durability due to the nonporous nature of this mate-
rial which does not allow cellular in-growth and thickening. Certain-
ly, long-term follow-up of this valve is mandatory to determine the 
true value of this new technique.
Timing of Pulmonary Valve Replacement
PVR is absolutely indicated when symptoms or decreased exer-
cise tolerance attributable to PR are present. However, there is in-
sufficient evidence and no detailed consensus to guide optimal 
timing of PVR in asymptomatic patients with repaired TOF and sig-
nificant PR. The recently published guidelines from the American 
College of Cardiology/American Heart Association state that PVR is 
reasonable in patients with severe PR in association with “moder-
Fig. 4. Durability of bioprosthetic valves in the pulmonary position. A: overall freedom from redo pulmonary valve replacement. B: overall freedom from 
both prosthetic valve failure and dysfunction. Numbers above the X-axis represent patients remaining at risk.
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Table 1. Summary of reported results for bioprosthetic pulmonary valve replacement
Author Patients No. Age (years) Valve type Valve size (mm) FU (years) Freedom from redo PVR
Fiore et al.
40) 49 23.0 Porcine 25 1.7 78% at 5 years
Kanter et al.
41) 38 11.4 Porcine 26 4.9 100% at 8 years
Allen et al.
42) 48 11.0 Bovine 26 3.6 100% at 5 years
Morales et al.
43) 26 20.3 Bovine 23 1.6 100% at 2.5 years
Hawkins et al.
44) 150 15.8 Stentless 27 NA 99% at 5 years
Kanter et al.
45) 56 11.8 Stentless 24 2.5 1 reoperation
Yemets et al.
46) 79 19.6 Mixed NA 5.8 86% at 10 years
Lee et al.
39) 181 14.2 Mixed 23 7.3 52% at 10 years
Age, valve size, and follow-up duration are expressed as mean values. PVR: pulmonary valve replacement, FU: follow-up, NA: not available
Fig. 5. Intraoperative view of completed bicuspid pulmonary valve implan-
tation using a 0.1 mm thickness polytetrafluoroethylene membrane. PV: 
pulmonary valve.5 Cheul Lee
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ate to severe RV dysfunction or enlargement”.
56) However, the spe-
cific thresholds for “moderate to severe RV dysfunction or enlarge-
ment” have not been defined. If PVR can be performed with ne-
gligible mortality and morbidity, and durable prosthetic valves are 
available, PVR should be recommended as early as possible for all 
patients with dilated RV. However, because this is not the case, we 
should decide the “upper threshold” to the point at which we can 
delay PVR and above which optimal outcome cannot be expected 
after PVR. Therrien and colleagues reported this “upper threshold” 
for the first time.
24) They found that in no patients with a RV end-di-
astolic volume index (EDVI) >170 mL/m
2 or a RV end-systolic volume 
index (ESVI) >85 mL/m
2 before PVR were RV volumes “normalized” 
after surgery. Oosterhof et al.
19) reported that normalization of RV 
volumes could be achieved when preoperative RV EDVI was <160 
mL/m
2 or RV ESVI was <82 mL/m
2. Geva et al.
7) reported that RV ESVI 
<90 mL/m
2 was associated with optimal outcome (normal RV size 
and function). Frigiola et al.
20) suggested the most aggressive policy 
of performing PVR when RV EDVI <150 mL/m
2. What about the “lo-
wer threshold” above which we should consider PVR? Definitely, it 
primarily depends upon the clinical status of an individual patient. 
In asymptomatic patients, Geva et al.
8) and Dave et al.
18) recom-
mended PVR when RV EDVI >150 mL/m
2. Although many studies 
identified cutoff values of RV EDVI as an indication for PVR, Geva 
et al.
7) and Henkens et al.
57) stressed the importance of RV ESVI in 
determining the timing of PVR. Other factors influencing the tim-
ing of PVR include moderate or severe tricuspid regurgitation, sus-
tained tachyarrhythmia, severe branch pulmonary artery stenosis, 
and large RV outflow tract aneurysm.
8)
Summary
PVR for patients with chronic PR after relief of RV outflow tract 
obstruction can be performed safely with low operative mortality 
and morbidity. PVR in these patients consistently leads to improve-
ment in the functional class and a substantial decrease or normal-
ization of RV volumes. Although currently there is no evidence sh-
owing the long-term survival benefit of PVR, timely PVR before 
severe RV dilatation and/or dysfunction occurs may have a benefi-
cial effect on QRS duration and RV function, consequently improv-
ing long-term survival. Suboptimal durability of currently used bio-
prosthetic valves is a weak aspect of determining the optimal ti-
ming of PVR. Optimal timing of PVR in asymptomatic patients needs 
to be further refined.
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